Thermo Fisher Scientific (NYSE:TMO) shares climbed 1.4% after the company posted third-quarter earnings that beat analyst forecasts, supported by stronger revenue and improved margins.
For the quarter ended September 27, 2025, the scientific equipment maker reported adjusted earnings per share of $5.79, surpassing the consensus estimate of $5.50 by $0.29. Revenue rose 5% year-over-year to $11.12 billion, ahead of the $10.91 billion expected, with organic growth of 3%.
“Our team did an outstanding job and delivered excellent operational performance in the quarter, reflecting the strength of our proven growth strategy, the power of our PPI Business System, and the continued active management of our company,” said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific.
The company’s adjusted operating margin increased to 23.3% from 22.3% in the same quarter last year, while GAAP EPS held steady at $4.27 compared with $4.25 in the prior-year period.
Thermo Fisher also rolled out several new products during the quarter, including the FDA-approved Oncomine Dx Express Test for non-small cell lung cancer and the Olink Target 48 Neurodegeneration panel for research on conditions such as Alzheimer’s and Parkinson’s disease.
In addition, the company reinforced its market position through strategic acquisitions, purchasing a Filtration and Separation business from Solventum and a sterile fill-finish site in Ridgefield, New Jersey, from Sanofi. It also repurchased $1.0 billion in stock and launched a strategic collaboration with OpenAI to expand the use of artificial intelligence across its operations.